公开(公告)号：US20220098277A1

公开(公告)日：2022-03-31

申请号：US17547376

申请日：2021-12-10

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  A61K39/00 ,  C07K14/47 ,  C07K14/635 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574 ,  A61K35/17

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220098276A1

公开(公告)日：2022-03-31

申请号：US17547372

申请日：2021-12-10

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  A61K39/00 ,  C07K14/47 ,  C07K14/635 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574 ,  A61K35/17

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220098275A1

公开(公告)日：2022-03-31

申请号：US17547315

申请日：2021-12-10

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  A61K39/00 ,  C07K14/47 ,  C07K14/635 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574 ,  A61K35/17

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220033469A1

公开(公告)日：2022-02-03

申请号：US17503020

申请日：2021-10-15

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  C12N5/0783 ,  G01N33/569 ,  A61K45/06 ,  C07K14/00 ,  C07K7/06 ,  A61K38/06 ,  C07K16/30 ,  G01N33/50 ,  C07K14/725 ,  C07K14/47 ,  C07K16/18 ,  C07K7/02 ,  A61K39/00 ,  C12Q1/6886 ,  A61K38/17 ,  A61K38/08 ,  A01N37/46 ,  G01N33/566 ,  C12N9/64 ,  C07K16/28

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220031824A1

公开(公告)日：2022-02-03

申请号：US17508230

申请日：2021-10-22

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K39/00 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0783 ,  C07K16/18 ,  C07K7/00 ,  A61K38/04 ,  G01N33/68 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  A61K35/17 ,  C07K7/06

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.

公开(公告)号：US20210403531A1

公开(公告)日：2021-12-30

申请号：US17458670

申请日：2021-08-27

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  C07K7/08 ,  C07K16/28 ,  G01N33/50 ,  A61K39/00 ,  C12N15/115 ,  C12N9/12 ,  C12Q1/6886 ,  C07K14/725 ,  C07K7/06 ,  C07K16/30 ,  C07K14/47 ,  C12N5/0783 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20210395337A1

公开(公告)日：2021-12-23

申请号：US17459150

申请日：2021-08-27

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  G01N33/569 ,  A61K39/00 ,  C07K16/28 ,  A61K45/06 ,  A01N37/46 ,  C07K14/725 ,  C12Q1/6886 ,  C07K14/47 ,  C07K16/30 ,  A61K38/08 ,  C07K7/02 ,  C07K7/06 ,  G01N33/566 ,  C07K16/18 ,  C12N5/0783 ,  C12N9/64 ,  C07K14/00 ,  A61K38/17 ,  G01N33/50 ,  A61K38/06

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20210380662A1

公开(公告)日：2021-12-09

申请号：US17401678

申请日：2021-08-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  C07K7/06 ,  C07K16/28 ,  C07K14/725 ,  C12N15/115 ,  C12N5/0783 ,  A61K39/00 ,  G01N33/574 ,  C12Q1/6886 ,  G01N33/50 ,  C07K7/08 ,  C07K16/30 ,  C07K14/47 ,  C12N9/12

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20210322527A1

公开(公告)日：2021-10-21

申请号：US17327190

申请日：2021-05-21

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C12N15/115 ,  C07K14/74 ,  C07K14/47 ,  C07K16/18

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20210317175A1

公开(公告)日：2021-10-14

申请号：US17351341

申请日：2021-06-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Oliver SCHOOR ,  Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/113 ,  C07K14/725 ,  C07K16/30

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.